Analysts’ Recent Ratings Updates for Waters (WAT)

A number of research firms have changed their ratings and price targets for Waters (NYSE: WAT):

  • 1/25/2018 – Waters had its “buy” rating reaffirmed by analysts at BTIG Research.
  • 1/24/2018 – Waters had its price target raised by analysts at Barclays PLC from $202.00 to $208.00. They now have an “equal weight” rating on the stock.
  • 1/24/2018 – Waters had its price target raised by analysts at Janney Montgomery Scott from $200.00 to $230.00. They now have a “buy” rating on the stock.
  • 1/24/2018 – Waters had its price target raised by analysts at JPMorgan Chase & Co. from $180.00 to $200.00. They now have a “neutral” rating on the stock.
  • 1/24/2018 – Waters had its price target raised by analysts at Robert W. Baird from $219.00 to $220.00. They now have an “outperform” rating on the stock.
  • 1/24/2018 – Waters had its price target raised by analysts at Citigroup Inc from $190.00 to $223.00. They now have a “neutral” rating on the stock.
  • 1/23/2018 – Waters had its “outperform” rating reaffirmed by analysts at William Blair.
  • 1/8/2018 – Waters had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $202.00 price target on the stock.
  • 1/6/2018 – Waters was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Waters Corp. has an excellent earnings history, having surpassed estimates in each of the trailing four quarters. Going forward, the company believes that stable demand from pharmaceutical business, steady recurring revenues, strength in Asia and modest recovery in industrial markets will accelerate its momentum. Based on these dynamics, the company is expecting strong mid-single-digit constant currency sales increase. Even the government and academic markets have returned to the growth track after sustained weakness. However, the company’s growth will likely be hindered by contracting demand in the Americas. Waters Corp. also intends to increase its spending on research and development in the coming quarters, which, although beneficial in the long run, will push expenses higher and hurt immediate profits. Further, shares of Waters Corp. have underperformed the industry’s average return over past six months.”
  • 1/5/2018 – Waters is now covered by analysts at BTIG Research. They set a “buy” rating and a $230.00 price target on the stock.
  • 1/3/2018 – Waters is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $198.00 price target on the stock.
  • 12/26/2017 – Waters was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $217.00 price target on the stock. According to Zacks, “Waters Corp. has an excellent earnings history, having surpassed estimates in each of the trailing four quarters. Going forward, the company believes that stable demand from pharmaceutical business, steady recurring revenues, strength in Asia and modest recovery in industrial markets will accelerate its momentum. Based on these dynamics, the company is expecting strong mid-single-digit constant currency sales increase. Even the government and academic markets have returned to the growth track after sustained weakness. Moreover, the company has been benefiting hugely from both of its LC and LC/MS platforms. Further, shares of the company have outperformed the industry’s average return over past year. However, the company’s growth will likely be hindered by contracting demand in the Americas. Also, currency headwinds are expected to somewhat hinder the company’s sales, going forward.”

Waters Co. (WAT) traded up $1.86 on Monday, hitting $195.45. The company had a trading volume of 53,690 shares, compared to its average volume of 544,016. The firm has a market cap of $15,396.80, a PE ratio of 1,028.74, a P/E/G ratio of 2.32 and a beta of 0.88. The company has a current ratio of 2.10, a quick ratio of 1.97 and a debt-to-equity ratio of 0.66. Waters Co. has a 1-year low of $148.72 and a 1-year high of $220.20.

Waters (NYSE:WAT) last announced its earnings results on Tuesday, January 23rd. The medical instruments supplier reported $2.51 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.07. Waters had a return on equity of 24.70% and a net margin of 0.88%. The firm had revenue of $687.28 million for the quarter, compared to analysts’ expectations of $671.98 million. During the same quarter in the prior year, the firm earned $2.21 EPS. Waters’s quarterly revenue was up 9.3% on a year-over-year basis. equities analysts expect that Waters Co. will post 8.16 earnings per share for the current fiscal year.

In related news, Director Joann A. Reed sold 1,386 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $194.07, for a total value of $268,981.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William J. Miller sold 3,500 shares of the stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $194.94, for a total value of $682,290.00. Following the completion of the sale, the director now owns 25,849 shares of the company’s stock, valued at $5,039,004.06. The disclosure for this sale can be found here. Insiders sold a total of 124,789 shares of company stock worth $26,083,647 over the last ninety days. Corporate insiders own 5.07% of the company’s stock.

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Receive News & Ratings for Waters Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply